Vasectomy ReversalPhase 4NCT04788823
The Impact of Prednisone on Semen Parameters and Pregnancy Rates Post Vasectomy Reversal
A Phase 4 study testing Prednisone in people with Vasectomy Reversal, run by Charitable Union for the Research and Education of Peyronie's Disease at 1 site in United States.
Trial summary
1. Determine impact of prednisone on semen parameters post vasectomy reversal (evaluated both using prednisone as a combined cohort as well as via 3 separate protocols). 2. Determine impact of prednisone on pregnancy rates post vasectomy reversal (evaluated both using prednisone as a combined cohort as well as via 3… Read more about this study
- Who is it for?
- Ages 18 to 65 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Vasectomy Reversal
- What is being tested?
- Prednisone
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 75 participants
- Where
- 1 siteUnited States
- Study dates
- 24 Feb 2021to 13 Aug 2026
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- Men only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Men undergoing a first-time vasectomy reversal at the Male Fertility and Peyronie's Clinic
- 18-65 years of age
- Current sexual partner with desire to achieve pregnancy immediately
- Intent of reversal to restore fertility
- Partner <36 years of age
- Partner with no known fertility issues
- Prior history of paternity
Who cannot join
- Current corticosteroid use
- Prior vasectomy reversal
- Prior chemotherapy
- Testosterone use within 1 year of the vasectomy reversal
- Solitary testicle
- History of diabetes mellitus
Show all 10Show fewer
- History of systemic fungal infection
- Hypertension
- Any degree of diagnosed renal insufficiency
- Partner on birth control within past 3 months
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Impact of Prednisone on Semen Parameters and Pregnancy Rates Post Vasectomy Reversal: A Randomized, Controlled Trial
- Determine impact of prednisone on semen parameters post vasectomy reversal (evaluated both using prednisone as a combined cohort as well as via 3 separate protocols).
- Determine impact of prednisone on pregnancy rates post vasectomy reversal (evaluated both using prednisone as a combined cohort as well as via 3 separate protocols).
- Assess adverse events with prednisone utilization
Read the detailed description
- Introduction
This document is a protocol for a randomized, controlled clinical trial. This study will be carried out in accordance with the procedures described in this protocol, applicable United States government regulations and Western International Review Board policies and procedures.
1.1 Background and Clinical Need for the Current Study
Currently, vasectomy reversals are a common surgical treatment performed to restore fertility in men who have previously undergone vasectomies. Post-operatively, sperm are seen in the ejaculate in the majority of men undergoing a reversal, however, sperm counts commonly fluctuate over time. In a percentage of men, counts will ultimately decline to 0 over time. Although the exact cause of this decline is unknown, it is felt to be secondary to tissue remodeling and/or inflammation leading to stenosis of the anastomotic repair. To address this issue, clinicians have used prednisone for several decades. Despite the long-standing use, very few publications have assessed the overall efficacy of this therapy on improving outcomes. The objective of the current study is to perform a much more robust assessment as to the true risks and benefits of this therapy in improving post-operative outcomes.
1.2 Investigational Treatments
Men who are post vasectomy reversal will be treated with either no therapy (control) or one of three separate protocols with prednisone.
1.3 Preliminary Data
A very limited amount of data exists regarding the efficacy of corticosteroids in improving outcomes post vasectomy reversal. The earliest known study involved the use of cortisone in 8 dogs who underwent vasovasostomy procedures. Results showed that 63% of vasa were patent in the steroid group compared to 43% in control animals (not statistically significant). A second study administered prednisone to 20 men post vasectomy reversal and compared against 20 men who had previously undergone reversal but were not treated with prednisone. Results showed improved sperm counts (statistically significant) without statistically significant differences in pregnancy rates. And finally, a third study performed a retrospective analysis in 89 men who underwent reversals over a period of 11 years. Results demonstrated increases in total motile sperm counts, with greater improvements noted among men who exhibited the presence of sperm at the time of prednisone administration compared to those with 0 sperm.
These data are limited by several factors. The first study listed also performed a pathologic analysis and failed to demonstrate any differences in the extent of fibrosis. The second study was performed in a sequential manner, where outcomes may have just been reflective of learning curve improvements, and improvements were no longer present after the steroid was discontinued. The third study was retrospective in nature, and therefore is limited by significant biases (i.e. only men with low counts received the treatment, which leads to an effect bias). All series were very small and lacked statistical power.
Despite these limited data, the use of prednisone post vasectomy reversal is a common, widespread practice among reversal surgeons.
1.4 Study Rationale and Risk Analysis (Risks to Benefits Ratio)
The study is currently designed to address an important clinical question. Specifically, does the addition of prednisone post-operatively lead to improved semen and pregnancy outcomes. Additionally, does the addition of prednisone lead to temporary or permanent improvements. Regarding potential risks, the use of prednisone will be limited to shorter durations of therapy. Potential risks in a young, healthy population are low. Specifically, an analysis of men 20-64 found that the risks of prednisone include 3 GI bleeds per 100 person years, <1 with a severe infection, and <1 with heart failure. Our study will not include as high of a dosage or duration of therapy shown in this prior risk study, and as such, the true risks are anticipated to be small (if any).
- Conditions
- Vasectomy Reversal
- Being tested
- Prednisone
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PrednisoneDrug
Treatment groups will be administered different dosages of Prednisone post vasectomy reversal.
| Study group | Role | What they receive |
|---|---|---|
| Control | No intervention | Group 1 will represent controls and will not receive prednisone in the 3-year post-op period. |
| Prednisone Monthly - Scheduled | Experimental | Group 2 will receive 3, one-month courses of prednisone (20 mg daily x 1 week, 10 mg daily x 1 week, 5 mg x 2 weeks). These will be given at the beginning of months 0, 2, and 4 and will be self-administered. Receives: Drug: Prednisone |
| Prednisone Monthly - As Needed | Experimental | Group 3 will receive a maximum of 3, one-month courses of prednisone (20 mg daily x 1 week, 10 mg daily x 1 week, 5 mg x 2 weeks). These will be administered based on sequential semen analyses. If a semen analysis demonstrates a drop in concentration from a prior analysis or if it shows a 0 concentration, the course will be administered. Receives: Drug: Prednisone |
| Prednisone Every Other Week | Experimental | Group 4 will receive alternating 1 week dosages of prednisone (1 week on, 1 week off - 5 mg daily only) for a total of 24 weeks Receives: Drug: Prednisone |
What is being measured
The primary outcome is the main question the study is designed to answer.
Impact of Prednisone on semen concentration post vasectomy reversal
Determine impact of prednisone on semen concentration post vasectomy reversal (evaluated both using prednisone as a combined cohort as well as via 3 separate protocols).
Measured: 3 years
Impact of prednisone on pregnancy rates post vasectomy reversal.
Determine impact of prednisone on pregnancy rates post vasectomy reversal (evaluated both using prednisone as a combined cohort as well as via 3 separate protocols).
Measured: 3 Years
Assess adverse events with prednisone utilization
Assess adverse events with prednisone utilization
Measured: 3 years
Secondary outcomes (3)
Impact of Prednisone on semen concentration post vasectomy reversal
Determine impact of prednisone on semen concentration post vasectomy reversal (evaluated both using prednisone as a combined cohort as well as via 3 separate protocols).
Measured: 1 year
Impact of prednisone on pregnancy rates post vasectomy reversal.
Determine impact of prednisone on pregnancy rates post vasectomy reversal (evaluated both using prednisone as a combined cohort as well as via 3 separate protocols).
Measured: 1 year
Impact of Prednisone on semen concentration post vasectomy reversal
Determine impact of prednisone on semen concentration post vasectomy reversal (evaluated both using prednisone as a combined cohort as well as via 3 separate protocols).
Measured: Up to 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Mar 2021
- Study start24 Feb 2021
- Primary completion13 Aug 2026
- Study completion13 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Vasectomy ReversalStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The study cohort will be randomized to one of 4 arms: control or 3 different drug protocols.
- Masking
- None (open label)
- Enrolment
- 75 participants (actual)
Sponsor and investigators
- Lead sponsor
- Charitable Union for the Research and Education of Peyronie's Disease
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Benjamin Green, Study director, The Male Fertility and Peyronie's Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04788823
- Sponsor's protocol ID
- CUREPD 102
- Status last verified
- Aug 2026
- First submitted
- 3 Mar 2021
- Last updated
- 26 Aug 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Trost L, Helo S, Brearton K, Warner R, Ziegelmann M, Kohler T, Savage J. Impact of prednisone on vasectomy reversal outcomes (iPRED study): results from a randomized, controlled clinical trial. Fertil Steril. 2025 May;123(5):804-811. doi: 10.1016/j.fertnstert.2024.11.019. Epub 2024 Nov 20.
PubMed 39577828
Study at a glance
From the registry record, last updated by the sponsor on 26 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Impact of Prednisone on Semen Parameters and Pregnancy Rates Post Vasectomy Reversal: A Randomized, Controlled Trial
- ClinicalTrials.gov ID
- NCT04788823
- Acronym / sponsor ID
- CUREPD 102
- Conditions
- Vasectomy Reversal
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 75 participants (actual)
- Lead sponsor
- Charitable Union for the Research and Education of Peyronie's DiseaseUniversity, hospital or other
- Study start
- 24 Feb 2021 (actual)
- Primary completion
- 13 Aug 2026 (actual)
- Study completion
- 13 Aug 2026 (actual)
- First posted
- 9 Mar 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- Determine impact of prednisone on semen parameters post vasectomy reversal (evaluated both using prednisone as a combined cohort as well as via 3 separate protocols).
- Determine impact of prednisone on pregnancy rates post vasectomy reversal (evaluated both using prednisone as a combined cohort as well as via 3 separate protocols).
- Assess adverse events with prednisone utilization
Detailed description
- Introduction
This document is a protocol for a randomized, controlled clinical trial. This study will be carried out in accordance with the procedures described in this protocol, applicable United States government regulations and Western International Review Board policies and procedures.
1.1 Background and Clinical Need for the Current Study
Currently, vasectomy reversals are a common surgical treatment performed to restore fertility in men who have previously undergone vasectomies. Post-operatively, sperm are seen in the ejaculate in the majority of men undergoing a reversal, however, sperm counts commonly fluctuate over time. In a percentage of men, counts will ultimately decline to 0 over time. Although the exact cause of this decline is unknown, it is felt to be secondary to tissue remodeling and/or inflammation leading to stenosis of the anastomotic repair. To address this issue, clinicians have used prednisone for several decades. Despite the long-standing use, very few publications have assessed the overall efficacy of this therapy on improving outcomes. The objective of the current study is to perform a much more robust assessment as to the true risks and benefits of this therapy in improving post-operative outcomes.
1.2 Investigational Treatments
Men who are post vasectomy reversal will be treated with either no therapy (control) or one of three separate protocols with prednisone.
1.3 Preliminary Data
A very limited amount of data exists regarding the efficacy of corticosteroids in improving outcomes post vasectomy reversal. The earliest known study involved the use of cortisone in 8 dogs who underwent vasovasostomy procedures. Results showed that 63% of vasa were patent in the steroid group compared to 43% in control animals (not statistically significant). A second study administered prednisone to 20 men post vasectomy reversal and compared against 20 men who had previously undergone reversal but were not treated with prednisone. Results showed improved sperm counts (statistically significant) without statistically significant differences in pregnancy rates. And finally, a third study performed a retrospective analysis in 89 men who underwent reversals over a period of 11 years. Results demonstrated increases in total motile sperm counts, with greater improvements noted among men who exhibited the presence of sperm at the time of prednisone administration compared to those with 0 sperm.
These data are limited by several factors. The first study listed also performed a pathologic analysis and failed to demonstrate any differences in the extent of fibrosis. The second study was performed in a sequential manner, where outcomes may have just been reflective of learning curve improvements, and improvements were no longer present after the steroid was discontinued. The third study was retrospective in nature, and therefore is limited by significant biases (i.e. only men with low counts received the treatment, which leads to an effect bias). All series were very small and lacked statistical power.
Despite these limited data, the use of prednisone post vasectomy reversal is a common, widespread practice among reversal surgeons.
1.4 Study Rationale and Risk Analysis (Risks to Benefits Ratio)
The study is currently designed to address an important clinical question. Specifically, does the addition of prednisone post-operatively lead to improved semen and pregnancy outcomes. Additionally, does the addition of prednisone lead to temporary or permanent improvements. Regarding potential risks, the use of prednisone will be limited to shorter durations of therapy. Potential risks in a young, healthy population are low. Specifically, an analysis of men 20-64 found that the risks of prednisone include 3 GI bleeds per 100 person years, <1 with a severe infection, and <1 with heart failure. Our study will not include as high of a dosage or duration of therapy shown in this prior risk study, and as such, the true risks are anticipated to be small (if any).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
- Model description
- The study cohort will be randomized to one of 4 arms: control or 3 different drug protocols.
| Arm | Type | Receives |
|---|---|---|
| Control | No intervention | –Group 1 will represent controls and will not receive prednisone in the 3-year post-op period. |
| Prednisone Monthly - Scheduled | Experimental | Drug: PrednisoneGroup 2 will receive 3, one-month courses of prednisone (20 mg daily x 1 week, 10 mg daily x 1 week, 5 mg x 2 weeks). These will be given at the beginning of months 0, 2, and 4 and will be self-administered. |
| Prednisone Monthly - As Needed | Experimental | Drug: PrednisoneGroup 3 will receive a maximum of 3, one-month courses of prednisone (20 mg daily x 1 week, 10 mg daily x 1 week, 5 mg x 2 weeks). These will be administered based on sequential semen analyses. If a semen analysis demonstrates a drop in concentration from a prior analysis or if it shows a 0 concentration, the course will be administered. |
| Prednisone Every Other Week | Experimental | Drug: PrednisoneGroup 4 will receive alternating 1 week dosages of prednisone (1 week on, 1 week off - 5 mg daily only) for a total of 24 weeks |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Men undergoing a first-time vasectomy reversal at the Male Fertility and Peyronie's Clinic
- 18-65 years of age
- Current sexual partner with desire to achieve pregnancy immediately
- Intent of reversal to restore fertility
- Partner <36 years of age
Key exclusion criteria (10 listed)
- Current corticosteroid use
- Prior vasectomy reversal
- Prior chemotherapy
- Testosterone use within 1 year of the vasectomy reversal
- Solitary testicle
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PrednisoneTreatment groups will be administered different dosages of Prednisone post vasectomy reversal. | Drug | Prednisone Every Other Week, Prednisone Monthly - As Needed, Prednisone Monthly - Scheduled |
Primary outcome
Impact of Prednisone on semen concentration post vasectomy reversal
Time frame: 3 years
Determine impact of prednisone on semen concentration post vasectomy reversal (evaluated both using prednisone as a combined cohort as well as via 3 separate protocols).
Impact of prednisone on pregnancy rates post vasectomy reversal.
Time frame: 3 Years
Determine impact of prednisone on pregnancy rates post vasectomy reversal (evaluated both using prednisone as a combined cohort as well as via 3 separate protocols).
Assess adverse events with prednisone utilization
Time frame: 3 years
Assess adverse events with prednisone utilization
3 secondary outcomes
Impact of Prednisone on semen concentration post vasectomy reversal
Time frame: 1 year
Impact of prednisone on pregnancy rates post vasectomy reversal.
Time frame: 1 year
Impact of Prednisone on semen concentration post vasectomy reversal
Time frame: Up to 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Aug 2026.
- Derived from this study: PubMed 39577828Trost L, Helo S, Brearton K, Warner R, Ziegelmann M, Kohler T, Savage J. Impact of prednisone on vasectomy reversal outcomes (iPRED study): results from a randomized, controlled clinical trial. Fertil Steril. 2025 May;123(5):804-811. doi: 10.1016/j.fertnstert.2024.11.019. Epub 2024 Nov 20.
- Individual participant dataSharing planned: No
Related trials for Vasectomy Reversal
RecruitingPhase 2
Plan A Occlusion and Reversal System Feasibility Study
Fertility, Fertility, Male
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Benjamin Green study director
The Male Fertility and Peyronie's Clinic
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Prednisone in people with Vasectomy Reversal, run by Charitable Union for the Research and Education of Peyronie's Disease at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Impact of Prednisone on semen concentration post vasectomy reversal (time frame: 3 years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04788823, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2026.